Kanazawa, Nobuo
Ishii, Taeko
Takita, Yasushi
Nishikawa, Atsushi
Nishikomori, Ryuta
Funding for this research was provided by:
Eli Lilly Japan
Article History
Received: 10 November 2022
Accepted: 6 April 2023
First Online: 22 April 2023
Declarations
:
: The protocol was approved by the institutional review boards prior to patient recruitment, and each patient provided written informed consent prior to enrollment. The study was conducted in accordance with consensus ethics principles derived from international ethics guidelines, including the Declaration of Helsinki and the International Ethical Guidelines by the Council for International Organizations of Medical Sciences and the International Council for Harmonisation E6 Guidelines for Good Clinical Practice.
: All named authors meet the International Committee of Medical Journal Editors (ICMJE) criteria for authorship of this article, take responsibility for the integrity of the work as a whole, and have given their approval for this version to be published.
: Taeko Ishii, Yasushi Takita, and Atushi Nishikawa are Lilly’s employees and shareholders of Eli Lilly and Company. Nobuo Kanazawa and Ryuta Nishikomori have no conflicting interests.